Bristol Myers Squibb announced that on December 6, its Board of Directors authorized the repurchase of an additional $3B of the company’s common stock under the company’s multi-year share repurchase program. With this increase, the company’s total outstanding share repurchase authorization is approximately $5B. The program enables management to execute repurchases at its discretion.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BMY:
- Bristol Myers says FDA accepts Opdivo combo sBLA for priority review
- Biotech Alert: Searches spiking for these stocks today
- Cabaletta Bio, Gracell slide as FDA probes risk of CAR T cell immunotherapies
- FDA probing risk of T-cell malignancy following CAR T cell immunotherapies
- Bristol-Myers (NYSE:BMY) Expands Collaboration with Avidity Bio in $2.3B Deal